Harrow (HROW)Divisadero Street Capital Management, LP opened a new position $4.29M

141K

Shares reported

0.27%

Disclosed portfolio weight

$4.29M

Reported value

Holdings as of

Jun 30, 2025

Filed

Aug 14, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Aug 11, 2025Company filing · Form 8-K · Results, Reg FDReported its results, and shared information with investors

What came next

1. Sep 5, 2025Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 1 more item)
2. Sep 8, 2025Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations (and 1 more item)
3. Sep 17, 2025Company filing · Form 8-K · Auditor changeChanged its auditor“On September 17, 2025, Harrow, Inc. (the “ Company ”), through action of the Audit Committee (the “ Audit Committee ”) of the Company’s Board of Directors, dismissed Crowe LLP (“ Crowe ”) as the Company’s independent registered public accounting firm, effective immediately.”
4. Sep 24, 2025Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them (and 1 more item)
5. Sep 26, 2025Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations
6. Oct 6, 2025Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On October 6, 2025, John Saharek ceased serving as President and Chief Executive Officer of ImprimisRx, LLC and certain affiliated entities, each of which is a wholly owned subsidiary of Harrow, Inc. (the “Company”), effective that date.”
7. Nov 17, 2025Company filing · Form 8-K · Acquisition or sale, Unregistered sharesCompleted buying or selling a business or assets, and sold new shares without registering them (and 1 more item)“On November 17, 2025, Harrow, Inc. (the “Company”) completed the previously announced acquisition of Melt Pharmaceuticals, Inc. (“Melt”) pursuant to the Agreement and Plan of Merger, dated September 24, 2025 (the “Merger Agreement”), by and among the Company, Harrow Acquisition Sub, Inc., Melt, and the stockholder representative.”

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Harrow

For Harrow, OQRO holds 2 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its HROW page.

How this filing works

• SEC Form 13F

Other disclosures at Harrow

• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRMay 12, 2026
• SEC Form 13F-HRFeb 9, 2026
• SEC Form 13F-HRNov 14, 2025
• SEC Form 13F-HRNov 12, 2025

Everything OQRO holds on this company is on its HROW page.